NCT06470048
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 19 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 106 → 96 locations
- Enrollment target: 201 to 203
- Minor Enrollment closed, study ongoing
- Trial sites reduced: 128 → 106 locations
- Enrollment target: estimated 200 to confirmed 201
Notable Eligibility criteria shortened, about 13 words Show 4 more changesShow less
- Primary endpoints: details revised at 1 of 1 entry
- Site details revised at 38 of 128 sites
- Publications: details revised at 1 of 1 entry
- Study description expanded, about 4 words
- Minor Site details revised at 8 of 128 sitesv17
- Minor Site details revised at 19 of 128 sitesv16
- Minor Site details revised at 42 of 128 sitesv15
- Minor Study completion pushed from Jul 15, 2030 to Jul 31, 2034
- Study sites: 127 to 128
- Primary completion date: Jul 6, 2027 to Jul 30, 2027
- Minor Study sites: 120 to 127v13
- Notable Primary completion date: Jul 10, 2028 to Jul 6, 2027
- Study sites: 116 to 120
- Minor Study sites: 109 to 116v11
- Minor Study sites: 103 to 109v10
- Minor Study sites: 96 to 103v9
- Minor Study sites: 83 to 96v8
- Notable Eligibility criteria expanded, about 64 words
- Study sites: 37 to 83
- Minor Study sites: 26 to 37v6
- Minor Study sites: 10 to 26v5
- Minor Study sites: 1 to 10
- Start date changed from estimate of Jul 31, 2024 to Oct 9, 2024
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Treatment Period 1: Ianalumab subcutaneous (s.c.) injection as defined in the protocol Treatment Period 2: Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol
Treatment Period 1: Placebo to Ianalumab subcutaneous (s.c.) injection as defined in the protocol Treatment Period 2: Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol
Drugs: Placebo, Ianalumab
Sites
96 sites in 25 countries
United States 14, Japan 10, Italy 7, China 6, Colombia 6, Brazil 5, India 5, Argentina 4, France 4, Mexico 4, Taiwan 4, Greece 3, South Korea 3, Spain 3, Germany 2, Hungary 2, Malaysia 2, Poland 2, Thailand 2, United Kingdom 2, Vietnam 2, Austria 1, Belgium 1, Portugal 1, Turkey (Türkiye) 1